Skip to main content

TAIKO PHARMACEUTICAL CO.,LTD.

大幸薬品株式会社

Valuation

Fundamental ratios for the latest reported period.

Ticker: 4574
FY2025 · 2025-12-31
Gross margin54.4%
Operating margin7.2%
Net margin14.4%
Return on equity11.3%
Return on assets7.5%
Revenue growth (YoY)1.7%
EPS (basic)¥18.38
EPS growth (YoY)2.7%
Current ratio3.36x
Equity ratio66.8%
Book value / share¥169.51
Free cash flow523 M